Review of cefditoren, an advanced-generation, broad-spectrum oral cephalosporin

Guay, David R.P.

doi:10.1016/s0149-2918(01)80147-8

Cited by 19 publications

(9 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Levofloxacin, cefotaxime, cefpodoxime, cefuroxime, amoxicillin/clavulanate and clarithromycin had good activity against the organisms tested. Cefditoren is also a very promising drug and could be an important alternative for the empirical treatment of bacterial respiratory tract infections since it has MIC values even lower than those showed by cefotaxime and it is active against S. pneumoniae [3,8,13]. The antimicrobial susceptibility of these organisms should be continuously monitored with emphasis on the activity of cefuroxime, amoxicillin/clavulanate, macrolides, tetracyclines, cotrimoxazole and fluoroquinolones as some isolates may show reduced susceptibility or be fully resistant to these drugs.…”

Section: Discussionmentioning

confidence: 99%

“…As increased rates of antibiotic resistant isolates have been described in countries from the south of Europe [1][2][3][4][5][6], we developed the Antibiotic Resistant Isolates in Southern European countries (ARISE) project as a point prevalence study that looked at isolates collected over a relatively narrow period of time. At the same time cefditoren, a new cephem antibiotic [7,8] was studied and this paper shows the results obtained with H. influenzae, H. parainfluenzae and M. catarrhalis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Antimicrobial susceptibility of Haemophilus influenzae, Haemophilus parainfluenzae and Moraxella catarrhalis isolated from adult patients with respiratory tract infections in four southern European countries

Soriano¹,

Granizo

Coronel

et al. 2004

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Antimicrobial susceptibility of Haemophilus influenzae, Haemophilus parainfluenzae and Moraxella catarrhalis isolated from adult patients with respiratory tract infections in four southern European countries

Soriano¹,

Granizo

Coronel

et al. 2004

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

“…In addition, we find that ester modification has a dramatic effect on anti-staphylococcal potency in vitro , suggesting that phosphonate transport limits the anti-bacterial efficacy of FSM and related compounds. Lipophilic ester modifications have previously been employed to improve pharmacokinetic properties and bioavailability of anti-staphylococcal agents (e.g., cefditoren pivoxil)(67). Since MEPicide ester modification at the site of infection is necessary to facilitate bacterial cell entry of inhibitors, future studies will aim to understand what chemical features drive intestinal and serum cleavage of the MEPicide prodrugs.…”

Section: Discussionmentioning

confidence: 99%

Potent, specific MEPicides for treatment of zoonotic staphylococci

Edwards¹,

Heueck²,

Lee

et al. 2019

Preprint

View full text Add to dashboard Cite

24Coagulase-positive staphylococci, which frequently colonize the mucosal surfaces of 25 animals, also cause a spectrum of opportunistic infections including skin and soft tissue 26 infections, urinary tract infections, pneumonia, and bacteremia. However, recent 27 45 robustly inhibit DXR in zoonotic staphylococci, and further, DXR represents a 46 promising, druggable target for future development. 3 47 48 Author Summary 49 The proliferation of microbial pathogens resistant to the current pool of antibiotics is a 50 major threat to public health. Drug resistance is pervasive in staphylococci, including 51 several species that can cause serious zoonotic infections in humans. Thus, new 52 antimicrobial agents are urgently need to combat these life-threatening, resistant 53 infections. Here we establish the MEP pathway as a promising new target against 54 zoonotic staphylococci. We determine that fosmidomycin (FSM) selectively targets the 55 isoprenoid biosynthesis pathway in zoonotic staphylococci, and use forward genetics to 56 identify the transporter that facilitates phosphonate antibiotic uptake. Employing this 57 knowledge, we synthesized a series of potent antibacterial prodrugs that circumvent 58 the transporter. Together, these novel prodrug inhibitors represent promising leads for 59 further drug development against zoonotic staphylococci. 60 61 65 zoonotic infections in humans that are clinically indistinguishable from infections with S. 66 aureus including pneumonia, skin and soft tissue infections, hardware infections, and 67 bacteremia(1-5). Newer clinical microbiological techniques, such as mass 68 spectrometry, now readily distinguish S. aureus from zoonotic coagulase-positive

show abstract

“…[1][2][3][4] In the clinic, cefditoren has been used for the treatment of streptococcal pharyngitis, acute maxillary sinusitis, acute otitis media, sinusitis, group A beta-hemolytic streptococcal pharyngotonsillitis, acute exacerbation of chronic bronchitis, and uncomplicated skin and skin structure infections in adult and adolescent patients. 1,5 In order to increase the bioavailability, cefditoren is oen converted into cefditoren pivoxil (a pivoxil ester). Aer oral administration, cefditoren pivoxil is hydrolysed by intestinal esterases to form cefditoren (an active metabolite).…”

Section: Introductionmentioning

confidence: 99%